Related Experiment Videos
Second cancers after breast cancer treatment
Sister Mary Andrew Matesich1, Charles L Shapiro
1Ohio Dominican College, Columbus, USA.
Seminars in Oncology
|December 10, 2003
Summary
Breast cancer treatments like radiation, chemotherapy, and tamoxifen may increase second cancer risk. However, benefits generally outweigh these risks, and modern methods reduce radiation-induced cancers.
Area of Science:
- Oncology
- Cancer Research
- Clinical Medicine
Background:
- Breast cancer treatments, including radiation, chemotherapy, and tamoxifen, are linked to a long-term increased risk of secondary malignancies.
- Awareness of these risks is crucial for clinicians and patients, despite the risks being relatively small.
Purpose of the Study:
- To evaluate the risks of second cancers associated with adjuvant breast cancer therapies.
- To inform clinicians and patients about the long-term implications of these treatments.
Main Methods:
- Review of data from tumor registries and studies on radiation-associated cancers.
- Analysis of risks linked to specific chemotherapy agents (alkylating agents, topoisomerase II inhibitors) and tamoxifen.
- Comparison of second cancer risks against the mortality benefits of adjuvant therapy.
Main Results:
- Postmastectomy radiation may slightly increase sarcoma or lung cancer risk after a decade; modern techniques minimize this.
- Adjuvant chemotherapy shows no increased solid tumor risk, but certain agents (cyclophosphamide, doxorubicin, epirubicin) are linked to rare leukemias.
- Tamoxifen use increases endometrial cancer risk (approx. 80 excess cases per 10,000 women over 10 years).
Conclusions:
- The benefits of adjuvant breast cancer therapy significantly outweigh the associated risks of second cancers.
- Further research is needed to personalize adjuvant therapy decisions and identify factors influencing second cancer development.